IQVIA Holdings Inc. (IQV)
USD 190.97
(-2.88%)
USD 190.97
(-2.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.25 Billion USD | 9.19% |
| 2022 | 2.88 Billion USD | 4.41% |
| 2021 | 2.74 Billion USD | 31.39% |
| 2020 | 2.06 Billion USD | 1.95% |
| 2019 | 1.88 Billion USD | 7.53% |
| 2018 | 1.88 Billion USD | 7.9% |
| 2017 | 1.65 Billion USD | 60.32% |
| 2016 | 906 Million USD | 39.46% |
| 2015 | 756.19 Million USD | 10.48% |
| 2014 | 711.36 Million USD | 24.62% |
| 2013 | 541.54 Million USD | 13.06% |
| 2012 | 500.08 Million USD | 11.48% |
| 2011 | 385.74 Million USD | -5.4% |
| 2010 | 467.37 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 788 Million USD | -9.12% |
| 2024 Q2 | 817 Million USD | 6.52% |
| 2024 Q3 | 797 Million USD | -2.33% |
| 2023 Q4 | 875 Million USD | 2.1% |
| 2023 Q3 | 857 Million USD | 4.13% |
| 2023 FY | - USD | 9.19% |
| 2023 Q1 | 773 Million USD | 0.0% |
| 2023 Q2 | 823 Million USD | 6.47% |
| 2022 Q4 | 773 Million USD | 7.36% |
| 2022 Q3 | 720 Million USD | 3.45% |
| 2022 Q2 | 696 Million USD | -6.95% |
| 2022 FY | - USD | 4.41% |
| 2022 Q1 | 748 Million USD | 1.91% |
| 2021 Q1 | 712 Million USD | 10.73% |
| 2021 Q2 | 663 Million USD | -6.88% |
| 2021 Q3 | 704 Million USD | 6.18% |
| 2021 Q4 | 734 Million USD | 4.26% |
| 2021 FY | - USD | 31.39% |
| 2020 Q4 | 643 Million USD | 18.85% |
| 2020 Q3 | 541 Million USD | 29.12% |
| 2020 Q2 | 419 Million USD | -22.12% |
| 2020 Q1 | 538 Million USD | -2.0% |
| 2020 FY | - USD | 1.95% |
| 2019 Q2 | 500 Million USD | -4.94% |
| 2019 FY | - USD | 7.53% |
| 2019 Q4 | 549 Million USD | 4.57% |
| 2019 Q3 | 525 Million USD | 5.0% |
| 2019 Q1 | 526 Million USD | 3.95% |
| 2018 Q4 | 506 Million USD | 9.52% |
| 2018 Q2 | 496 Million USD | 1.43% |
| 2018 FY | - USD | 7.9% |
| 2018 Q1 | 489 Million USD | 0.41% |
| 2018 Q3 | 462 Million USD | -6.85% |
| 2017 Q2 | 443 Million USD | 5.98% |
| 2017 Q4 | 487 Million USD | 5.41% |
| 2017 Q1 | 418 Million USD | -10.23% |
| 2017 Q3 | 462 Million USD | 4.29% |
| 2017 FY | - USD | 60.32% |
| 2016 FY | - USD | 39.46% |
| 2016 Q3 | 198.02 Million USD | -6.39% |
| 2016 Q2 | 211.53 Million USD | 0.83% |
| 2016 Q1 | 209.78 Million USD | 8.12% |
| 2016 Q4 | 465.63 Million USD | 135.14% |
| 2015 Q1 | 182.6 Million USD | 11.24% |
| 2015 Q4 | 194.02 Million USD | -9.32% |
| 2015 Q3 | 213.96 Million USD | 16.01% |
| 2015 Q2 | 184.43 Million USD | 1.0% |
| 2015 FY | - USD | 10.48% |
| 2014 Q3 | 189.49 Million USD | 11.64% |
| 2014 Q2 | 169.73 Million USD | -4.38% |
| 2014 Q1 | 177.51 Million USD | 8.98% |
| 2014 FY | - USD | 24.62% |
| 2014 Q4 | 164.14 Million USD | -13.38% |
| 2013 Q4 | 162.88 Million USD | 3.3% |
| 2013 Q1 | 144.49 Million USD | 13.3% |
| 2013 FY | - USD | 13.06% |
| 2013 Q2 | 122.96 Million USD | -14.9% |
| 2013 Q3 | 157.67 Million USD | 28.23% |
| 2012 FY | - USD | 11.48% |
| 2012 Q1 | 117.79 Million USD | 0.0% |
| 2012 Q4 | 127.53 Million USD | -2.96% |
| 2012 Q2 | 143.34 Million USD | 21.7% |
| 2012 Q3 | 131.42 Million USD | -8.32% |
| 2011 FY | - USD | -5.4% |
| 2010 FY | - USD | 0.0% |
| 2001 Q3 | 716 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Agilent Technologies, Inc. | 1.67 Billion USD | -94.156% |
| Charles River Laboratories International, Inc. | 1.03 Billion USD | -215.468% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | -87.991% |
| Danaher Corporation | 7.54 Billion USD | 56.857% |
| Enzo Biochem, Inc. | -8.34 Million USD | 39103.354% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | -141.292% |
| Mettler-Toledo International Inc. | 1.18 Billion USD | -175.196% |
| Qiagen N.V. | 650.58 Million USD | -400.474% |
| Revvity, Inc. | 813.25 Million USD | -300.367% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 69.852% |
| Waters Corporation | 1.02 Billion USD | -218.513% |